1. Home
  2. ENTX vs INTT Comparison

ENTX vs INTT Comparison

Compare ENTX & INTT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

N/A

Current Price

$2.85

Market Cap

147.4M

Sector

Health Care

ML Signal

N/A

Logo inTest Corporation

INTT

inTest Corporation

N/A

Current Price

$11.90

Market Cap

148.4M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ENTX
INTT
Founded
2010
1981
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
147.4M
148.4M
IPO Year
2015
1997

Fundamental Metrics

Financial Performance
Metric
ENTX
INTT
Price
$2.85
$11.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
3
Target Price
$9.75
★ $19.67
AVG Volume (30 Days)
★ 389.5K
90.0K
Earning Date
11-13-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.22
0.06
Revenue
$42,000.00
★ $66,801,000.00
Revenue This Year
N/A
$21.53
Revenue Next Year
N/A
$7.05
P/E Ratio
★ $12.05
$193.83
Revenue Growth
N/A
★ 66.06
52 Week Low
$0.91
$7.07
52 Week High
$4.20
$20.00

Technical Indicators

Market Signals
Indicator
ENTX
INTT
Relative Strength Index (RSI) 51.28 52.90
Support Level $2.71 $11.17
Resistance Level $3.12 $11.83
Average True Range (ATR) 0.18 0.47
MACD -0.02 0.18
Stochastic Oscillator 56.14 88.82

Price Performance

Historical Comparison
ENTX
INTT

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

About INTT inTest Corporation

inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.

Share on Social Networks: